How times have changed after my November 25, 2022, Buy Out Of Favour West Pharmaceutical post! In that post, I noted that West Pharmaceutical's (WST) short-term headwinds had led to its valuation retracing to a reasonable level and that I had initiated a 100-share position @ ~$225/share in one of the 'Core' accounts within the [...]
I last reviewed S&P Global (SPGI) in my October 31, 2022 post at which time I considered shares to be attractively valued. It continues to have an attractive long-term outlook despite short-term Ratings Division headwinds. However, shares are not attractively valued. I like to accumulate shares in great companies when they experience short-term headwinds; SPGI [...]
I would have preferred to wait for the release of Stryker's (SYK) FY2022 Form 10-K. However, I have sufficient information in its January 31, 2023 Q4 2022 Form 8-K and the Form 10-Ks from prior years by which to make an investment decision. In this post, I point out several observations that convinced me SYK [...]
With 17 consecutive years of record revenues, operating income, and adjusted EPS, expect consistent growth from Intercontinental Exchange (ICE). When I last reviewed ICE, it had just released Q2 and YTD2022 results. I now revisit it given the February 2, 2023 release of Q4 and FY2022 results and 2023 guidance. Business Overview Part 1 of [...]
I last reviewed Moody's Corporation (MCO) in this July 26, 2022 post at which time MCO had just released Q2 and YTD2022 results. Based on this analysis of MCO's Q4 and FY2022 results and FY2023 outlook released on January 31, 2023, I am not adding to my exposure because the current valuation is not justified. [...]
I last reviewed CVX in my August 18, 2022 guest post at Dividend Power at which time I concluded that the oil and gas demise was overblown. Following the January 27 release of Chevron's (CVX) exceptional FY2022 results, there appears to be a bit too much euphoria. This certainly was evident when CVX announced its [...]
I wrote a brief Blackstone (BX) post on December 1 in which I share why negative headlines leading to a decline in BX's share price present investors with a buying opportunity. When investing in BX, however, an investment must be for the long term. I say this because of the recent intense focus on the [...]
I last reviewed Automatic Data Processing (ADP) in my October 31, 2022 post at which time Q1 results and the revised FY2023 outlook had just been released. Based on my analysis I deemed ADP to be slightly overvalued. On January 25, ADP released Q2 and YTD2023 results and provided an update to its FY2023 outlook. [...]
I last reviewed Lockheed Martin (LMT) in this October 18, 2022 post. LMT has now released Q4 and FY2022 results and its FY2023 outlook on January 24. Despite supply chain headwinds, growth in the order backlog is encouraging. In this post, I look at whether I should add to my LMT exposure. I have also [...]
I last reviewed Raytheon Technologies (RTX) in this July 27, 2022 post. With the January 24, 2022 release of Q4 and FY2022 results and FY2023 outlook, I revisit it to determine whether I should add to my exposure. Business Overview Investors unfamiliar with RTX are encouraged to review the company's website and Part 1 Item [...]